Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
Clinical trial NCT00996957 · COMPLETED
Trial details
- NCT number
- NCT00996957
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-10-01
- Primary completion
- 2012-06-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.